Read and report vaccine reactions, harassment and failures.
In the U.S. today, the polio vaccine is usually administered in a combination shot that also contain vaccines for diphtheria (D), tetanus (T), and pertussis (whooping cough) (P). Additional vaccines may also include Haemophilus influenzae Type B (HIB) and/or hepatitis B vaccine.
Contraindications and precautions to vaccination as listed in the vaccine manufacturer product inserts
Pediarix (Diphtheria and tetanus toxoids and acellular pertussis, hepatitis B recombinant and inactivated poliovirus vaccine manufactured by GlaxoSmithKline.)
- Temperature of 105 F. or higher within 48 hours of a previous pertussis vaccination, not attributable to another identifiable cause;
- Collapse or shock-like state (hypotonic-hyporesponsive episodes) within 48 hours of a previous pertussis vaccination;
- Persistent crying lasting 3 hours or more within 48 hours of a previous pertussis vaccination;
- Convulsions with or without fever, occurring within 3 days of a previous pertussis vaccination;
- Serious allergic reaction to a previous pertussis vaccination;
- Encephalopathy (coma, decreased level of consciousness, prolonged convulsions) within 7 days of a previous pertussis vaccination not attributable to another identifiable cause;
- Children with a progressive neurologic disorder (such as infantile spasms, uncontrolled epilepsy, or progressive encephalopathy);
- Sensitivity to any component of Pediarix, including yeast or neomycin and polymyxin B (antibiotics);
- Apnea following intramuscular vaccination has been observed in some infants born prematurely. The Pediarix vaccine product insert warns that the decision to vaccinate an infant born prematurely should take into consideration both the potential risks and possible benefits of vaccination.
- The tip caps of prefilled Pediarix syringes contain latex and may cause an allergic reaction in persons sensitive to latex;
- If Guillain-Barré syndrome (GBS) occurred within 6 weeks of receiving a tetanus containing vaccine, assessment of the possible risks and potential benefits of receiving Pediarix should be carefully considered prior to vaccination.
Pediarix is FDA approved for use in infants and children 6 weeks through 6 years of age. Pediarix should not be administered to infants younger than 6 weeks or children older than 6 years of age.
Kinrix (Diphtheria and tetanus toxoids, acellular pertussis and inactivated poliovirus vaccine manufactured by GlaxoSmithKline.)
- Temperature of 105 F. or higher within 48 hours of a previous pertussis vaccination, not attributable to another identifiable cause;
- Collapse or shock-like state (hypotonic-hyporesponsive episodes) within 48 hours of a previous pertussis vaccination;
- Persistent crying lasting 3 hours or more within 48 hours of a previous pertussis vaccination;
- Convulsions with or without fever, occurring within 3 days of a previous pertussis vaccination;
- Serious allergic reaction to a previous pertussis vaccination;
- Encephalopathy (coma, decreased level of consciousness, prolonged convulsions) within 7 days of a previous pertussis vaccination not attributable to another identifiable cause;
- Children with a progressive neurologic disorder (such as infantile spasms, uncontrolled epilepsy, or progressive encephalopathy);
- Severe allergic reaction to any component of Kinrix, including neomycin and polymyxin B (antibiotics);
- The tip caps of prefilled Kinrix syringes contain latex and may cause an allergic reaction in persons sensitive to latex;
- If Guillain-Barré syndrome (GBS) occurred within 6 weeks of receiving a tetanus containing vaccine, assessment of the possible risks and potential benefits of receiving Kinrix should be carefully considered prior to vaccination.
Kinrix is FDA approved for use in children between the ages of 4 and 6 years. Kinrix should not be administered to children younger than 4 years or older than 6 years of age.
Quadracel (Diphtheria and tetanus toxoid, acellular pertussis and inactivated poliovirus vaccine manufactured by Sanofi Pasteur.)
- Serious allergic reaction following administration of a pertussis, tetanus, diphtheria, or polio containing vaccine or any ingredient of Quadracel vaccine;
- Encephalopathy (coma, decreased level of consciousness, prolonged convulsions) within 7 days of a previous pertussis vaccination not attributable to another identifiable cause;
- Children with a progressive neurologic disorder (such as infantile spasms, uncontrolled epilepsy, or progressive encephalopathy);
- Seizures within 3 days of a previous pertussis vaccination;
- Temperature of 105 F. or higher within 48 hours of a previous pertussis vaccination, not attributable to another identifiable cause;
- If Guillain-Barré syndrome (GBS) occurred within 6 weeks of receiving a tetanus containing vaccine, assessment of the possible risks and potential benefits of receiving Quadracel should be carefully considered prior to vaccination.
Quadracel is FDA approved for use in children between the ages of 4 and 6 years. Quadracel should not be administered to children younger than 4 years or older than 6 years of age.
Pentacel (Diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus and Haemophilus b conjugate (tetanus toxoid conjugate) vaccine manufactured by Sanofi Pasteur.)
- Temperature of 105 F. or higher within 48 hours of a previous pertussis vaccination, not attributable to another identifiable cause;
- Collapse or shock-like state (hypotonic-hyporesponsive episodes) within 48 hours of a previous pertussis vaccination;
- Persistent crying lasting 3 hours or more within 48 hours of a previous pertussis vaccination;
- Convulsions with or without fever, occurring within 3 days of a previous pertussis vaccination;
- Serious allergic reaction to a previous pertussis vaccination;
- Encephalopathy (coma, decreased level of consciousness, prolonged convulsions) within 7 days of a previous pertussis vaccination not attributable to another identifiable cause;
- Children with a progressive neurologic disorder (such as infantile spasms, uncontrolled epilepsy, or progressive encephalopathy)
- Severe allergic reaction to any component of Pentacel, including neomycin and polymyxin B (antibiotics);
- Apnea following intramuscular vaccination has been observed in some infants born prematurely. Pentacel vaccine product insert warns that the decision to vaccinate an infant born prematurely should take into consideration both the potential risks and possible benefits of vaccination;
- If Guillain-Barré syndrome (GBS) occurred within 6 weeks of receiving a tetanus containing vaccine, assessment of the possible risks and potential benefits of receiving Pentacel should be carefully considered prior to vaccination.
Pentacel is FDA approved for use in infants and children 6 weeks through 4 years of age. Pentacel should not be administered to infants younger than 6 weeks or children older than 4 years of age.
VAXELIS (Diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, Haemophilus b conjugate, and hepatitis B recombinant vaccine manufactured by MCM Vaccine Company.)
- Temperature of 105 F. or higher within 48 hours of a previous pertussis vaccination, not attributable to another identifiable cause;
- Collapse or shock-like state (hypotonic-hyporesponsive episodes) within 48 hours of a previous pertussis vaccination;
- Persistent crying lasting 3 hours or more within 48 hours of a previous pertussis vaccination;
- Convulsions with or without fever, occurring within 3 days of a previous pertussis vaccination;
- Serious allergic reaction to a previous dose of VAXELIS, any ingredient found in VAXELIS, or any other tetanus toxoid, diphtheria toxoid, pertussis-containing vaccine, hepatitis B vaccine, inactivated poliovirus vaccine, or H. influenzae type b vaccine;
- Encephalopathy (coma, decreased level of consciousness, prolonged convulsions) within 7 days of a previous pertussis vaccination not attributable to another identifiable cause;
- Children with a progressive neurologic disorder (such as infantile spasms, uncontrolled epilepsy, or progressive encephalopathy);
- Apnea following intramuscular vaccination has been observed in some infants born prematurely. The VAXELIS vaccine product insert warns that the decision to vaccinate an infant born prematurely should take into consideration both the potential risks and possible benefits of vaccination;
- If Guillain-Barré syndrome (GBS) occurred within 6 weeks of receiving a tetanus containing vaccine, assessment of the possible risks and potential benefits of receiving VAXELIS should be carefully considered prior to vaccination.
VAXELIS is FDA approved for use in infants and children 6 weeks through 4 years of age. VAXELIS should not be administered to infants younger than 6 weeks or children older than 4 years of age.
IPOL (inactive poliovirus (Monkey Kidney Cell) manufactured by Sanofi Pasteur)
- Hypersensitivity to any ingredient found within the vaccine, including polymyxin B, neomycin, streptomycin, formaldehyde, and 2-phenoxyethanol
- Anaphylaxis or anaphylactic shock occurring within 24 hours of a previous vaccine dose
- Acute febrile illness – vaccination should be deferred until a person has recovered
IPOL is FDA approved for use in individuals 6 weeks of age and older. IPOL should not be administered to infants younger than 6 weeks.
IMPORTANT NOTE: NVIC encourages you to become fully informed about Polio and the Polio vaccine by reading all sections in the Table of Contents, which contain many links and resources such as the manufacturer product information inserts, and to speak with one or more trusted health care professionals before making a vaccination decision for yourself or your child. This information is for educational purposes only and is not intended as medical advice.